세계의 세포 용해/세포 분획 시장 규모 : 세포 유형별, 최종 사용자별, 제품별, 지역별, 범위 및 예측

Cell Lysis/Cell Fractionation Market Size And Forecast

Cell Lysis/Cell Fractionation Market size was valued at USD 4.55 Billion in 2023 and is calculated to reach USD 6.3 Billion by 2030, expanding at a CAGR of 7.2% from 2024 to 2030. The market's growth is attributed to the growing number of cultured cell procedures used for commercial diagnostic and analytical applications. The continued rise in the prevalence of various ailments and the demand for novel therapies are projected to drive market expansion throughout the forecast period. Additionally, the growing advances in cell biology research and increased demand for protein analysis due to the increasing prevalence of various chronic and non-chronic conditions are expected to positively influence the market's growth.

Global Cell Lysis/Cell Fractionation Market Definition

Cell lysis and fractionation are related techniques that have applications in cell biology to open and separate cells and their components. Cell lysis refers to breaking the cells open to release the components in the cell, such as nucleic acid, proteins, and cell organelles. The cell's opening is done chemically, mechanically, or enzymatically. Cell lysis is an essential step in several research applications, such as drug development, protein purification, and DNA isolation.

Cell fractionation refers to separating different components of the cell after lysis. The process is carried out through density gradient centrifugation, differential centrifugation, and other methods to isolate subcellular or specific organelles. The fractions of the obtained materials can then be used for further analysis.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Cell Lysis/Cell Fractionation Market Overview

The growing demand for personalized medicine among the population is a key driver for the market. Personalized medicine offers several advantages, such as tailored treatments, early disease detection, reduced healthcare costs, improved drug development, and more efficient clinical trials. Personalized medicines allow healthcare professionals to provide tailored treatment to patients. The treatment is based on lifestyle, specific genetic makeup, and other factors; these factors help to improve the treatment outcomes and reduce the risk of side effects of the drugs. Cell lysis has applications in personalized medicines for extracting and isolating specific molecules or cell types relevant to a patient's treatment and diagnosis.

Growing investments by public and private institutions for research in life sciences are anticipated to impact market growth positively. For instance, in March 2023, the UK government announced funding of GBP 277 Million, wherein the government will contribute GBP 17 Million. The remaining 260 million will be provided through private investments for life science manufacturing projects, minimizing environmental impact, boosting health resilience, and deploying innovations, contributing to the country's growth. The funding is anticipated to support the country's economy by providing more than 500 jobs nationwide.

Additionally, the increasing prevalence of chronic conditions such as cancer, diabetes, cardiovascular diseases, and arthritis, among others, is expected to impact the market growth positively. Cell lysis and fractionation are key steps used to diagnose chronic conditions. For example, diagnosis of autoimmune diseases such as rheumatoid arthritis and cell lysis can be used to isolate autoimmune cells from the patient's blood and extract the DNA or RNA for gene expression analysis. The step helps identify specific proteins and genes that are either over or under-expressed in the immune cells, helping diagnose the disease and develop personalized medicine.

Global Cell Lysis/Cell Fractionation Market: Segmentation Analysis

The Global Cell Lysis/Cell Fractionation Market is Segmented on the basis of Type Of Cell, End User, Product, and Geography.

Cell Lysis/Cell Fractionation Market, By Type Of Cell

• Mammalian Cells
• Microbial Cells
• Others

Based on Type Of Cell, the market is bifurcated into Mammalian Cells, Microbial Cells, and Others. The mammalian cells segment accounted for the highest share in 2022 and is calculated to grow lucratively during the forecast period. The applications of these cells for the bio-manufacturing of vaccines, therapeutic proteins, and other recombinant products are key factors driving the segment's growth.

Cell Lysis/Cell Fractionation Market, By End User

• Research Laboratories and Institutes
• Biopharmaceutical and Biotechnology Companies
• Others

Based on End User, the market is bifurcated into Research Laboratories and Institutes, Biopharmaceutical and Biotechnology Companies, and Others. The Research Laboratories and Institutes segment held the largest market share in 2022 and is calculated to grow lucratively during the forecast period. The growing number of biotechnology institutes and many research activities undertaken by these institutes are driving the market's growth.

Cell Lysis/Cell Fractionation Market, By Product

• Instruments
• Sonicator
• Homogenizers
• Other Instruments
• Consumables
• Reagents and Kits
• Beads
• Disposables

Based on Product, the market is bifurcated into Instruments and Consumables. Instruments are classified into sonicators, homogenizers, and other instruments. Consumables are further differentiated into reagents & kits, beads, and disposables. The consumables segment accounted for the highest share in 2022 and is projected to grow lucratively during the forecast period. Repeated purchases, increased funding for cell-based research activities, and the increasing instances of chronic conditions among the population are factors driving the segment's growth.

Cell Lysis/Cell Fractionation Market, By Geography

• North America
• Europe
• Asia Pacific
• Middle East and Africa
• Latin America
• On the basis of Regional Analysis, The Global Cell Lysis/Cell Fractionation Market is classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. North America held the highest share in 2022 and is projected to grow lucratively during the forecast period owing to the technologically advanced R&D infrastructure. Moreover, the regional governments are also providing funding for the development of infrastructure and research projects, which is expected to impact market growth positively.

Key Players

• The "Global Cell Lysis/Cell Fractionation Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Thermo Fisher Scientific Inc., Merck KGAA, Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., Becton, Dickinson and Company, Cell Signaling Technology, Inc., MiltenyiBiotec, Roche Diagnostics, Qiagen N.V., and Qsonica, LLC., among others.
• This section provides a company overview, ranking analysis, company regional and industry footprint, and ACE Matrix.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

Key Developments

• In November 2022, Merck announced it would acquire Imago BioSciences Inc. The acquisition will help Merck to gain an edge over its competitors for clinical development.
• Ace Matrix Analysis
• The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as
• Active, Cutting Edge, Emerging, and Innovators.
• Market Attractiveness
• The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Cell Lysis/Cell Fractionation Market. We cover the major impacting factors driving the industry growth in the given region.
• Porter's Five Forces
• The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape in the Global Cell Lysis/Cell Fractionation Market, gauge the attractiveness of a particular sector, and assess investment possibilities.

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL CELL LYSIS/CELL FRACTIONATION MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL CELL LYSIS/CELL FRACTIONATION MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porter's Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL CELL LYSIS/CELL FRACTIONATION MARKET, BY TYPE OF CELL

• 6.1 Overview
• 6.2 Mammalian Cells
• 6.3 Microbial Cells
• 6.4 Others

6 GLOBAL CELL LYSIS/CELL FRACTIONATION MARKET, BY END USER

• 7.1 Overview
• 7.2 Research Laboratories and Institutes
• 7.3 Biopharmaceutical and Biotechnology Companies
• 7.4 Others

7 GLOBAL CELL LYSIS/CELL FRACTIONATION MARKET, BY PRODUCT

• 7.1 Overview
• 7.2 Instruments
  • 7.2.1 Sonicator
  • 7.2.2 Homogenizers
  • 7.2.3 Other Instruments
• 7.3 Consumables
  • 7.3.1 Reagents and Kits
  • 7.3.2 Beads
  • 7.3.3 Disposables

8 GLOBAL CELL LYSIS/CELL FRACTIONATION MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 The U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 The U.K.
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Argentina
  • 8.5.3 Rest of LATAM
• 8.6 Middle East and Africa
  • 8.6.1 UAE
  • 8.6.2 Saudi Arabia
  • 8.6.3 South Africa
  • 8.6.4 Rest of the Middle East and Africa

9 GLOBAL CELL LYSIS/CELL FRACTIONATION MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies
• 9.4 Company Regional Footprint
• 9.5 Company Industry Footprint
• 9.6 ACE Matrix

10 COMPANY PROFILES

• 10.1 Thermo Fisher Scientific Inc.
  • 10.1.1 Company Overview
  • 10.1.2 Company Insights
  • 10.1.3 Business Breakdown
  • 10.1.4 Product Benchmarking
  • 10.1.5 Key Developments
  • 10.1.6 Winning Imperatives
  • 10.1.7 Current Focus & Strategies
  • 10.1.8 Threat from Competition
  • 10.1.9 SWOT Analysis
• 10.2 Merck KGAA
  • 10.2.1 Company Overview
  • 10.2.2 Company Insights
  • 10.2.3 Business Breakdown
  • 10.2.4 Product Benchmarking
  • 10.2.5 Key Developments
  • 10.2.6 Winning Imperatives
  • 10.2.7 Current Focus & Strategies
  • 10.2.8 Threat from Competition
  • 10.2.9 SWOT Analysis
• 10.3 Bio-Rad Laboratories, Inc.
  • 10.3.1 Company Overview
  • 10.3.2 Company Insights
  • 10.3.3 Business Breakdown
  • 10.3.4 Product Benchmarking
  • 10.3.5 Key Developments
  • 10.3.6 Winning Imperatives
  • 10.3.7 Current Focus & Strategies
  • 10.3.8 Threat from Competition
  • 10.3.9 SWOT Analysis
• 10.4 Beckman Coulter, Inc.
  • 10.4.1 Company Overview
  • 10.4.2 Company Insights
  • 10.4.3 Business Breakdown
  • 10.4.4 Product Benchmarking
  • 10.4.5 Key Developments
  • 10.4.6 Winning Imperatives
  • 10.4.7 Current Focus & Strategies
  • 10.4.8 Threat from Competition
  • 10.4.9 SWOT Analysis
• 10.5 Becton, Dickinson, and Company
  • 10.5.1 Company Overview
  • 10.5.2 Company Insights
  • 10.5.3 Business Breakdown
  • 10.5.4 Product Benchmarking
  • 10.5.5 Key Developments
  • 10.5.6 Winning Imperatives
  • 10.5.7 Current Focus & Strategies
  • 10.5.8 Threat from Competition
  • 10.5.9 SWOT Analysis
• 10.6 Cell Signaling Technology, Inc.
  • 10.6.1 Company Overview
  • 10.6.2 Company Insights
  • 10.6.3 Business Breakdown
  • 10.6.4 Product Benchmarking
  • 10.6.5 Key Developments
  • 10.6.6 Winning Imperatives
  • 10.6.7 Current Focus & Strategies
  • 10.6.8 Threat from Competition
  • 10.6.9 SWOT Analysis
• 10.7 MiltenyiBiotec
  • 10.7.1 Company Overview
  • 10.7.2 Company Insights
  • 10.7.3 Business Breakdown
  • 10.7.4 Product Benchmarking
  • 10.7.5 Key Developments
  • 10.7.6 Winning Imperatives
  • 10.7.7 Current Focus & Strategies
  • 10.7.8 Threat from Competition
  • 10.7.9 SWOT Analysis
• 10.8 Roche Diagnostics
  • 10.8.1 Company Overview
  • 10.8.2 Company Insights
  • 10.8.3 Business Breakdown
  • 10.8.4 Product Benchmarking
  • 10.8.5 Key Developments
  • 10.8.6 Winning Imperatives
  • 10.8.7 Current Focus & Strategies
  • 10.8.8 Threat from Competition
  • 10.8.9 SWOT Analysis
• 10.9 Qiagen N.V.
  • 10.9.1 Company Overview
  • 10.9.2 Company Insights
  • 10.9.3 Business Breakdown
  • 10.9.4 Product Benchmarking
  • 10.9.5 Key Developments
  • 10.9.6 Winning Imperatives
  • 10.9.7 Current Focus & Strategies
  • 10.9.8 Threat from Competition
  • 10.9.9 SWOT Analysis
• 10.10 Qsonica, LLC
  • 10.10.1 Company Overview
  • 10.10.2 Company Insights
  • 10.10.3 Business Breakdown
  • 10.10.4 Product Benchmarking
  • 10.10.5 Key Developments
  • 10.10.6 Winning Imperatives
  • 10.10.7 Current Focus & Strategies
  • 10.10.8 Threat from Competition
  • 10.10.9 SWOT Analysis

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 Appendix

Related Research